Suppr
超能文献

Cilengitide in glioblastoma: when did it fail?

作者信息

Chinot Olivier L

机构信息

Aix-Marseille University, AP-HM, Department of Neuro-Oncology, CHU Timone, 13005 Marseille, France.

出版信息

Lancet Oncol. 2014 Sep;15(10):1044-5. doi: 10.1016/S1470-2045(14)70403-6. Epub 2014 Aug 19.

DOI:10.1016/S1470-2045(14)70403-6

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Cilengitide in glioblastoma: when did it fail?

Lancet Oncol. 2014 Sep;15(10):1044-5. doi: 10.1016/S1470-2045(14)70403-6. Epub 2014 Aug 19.

2

Does cilengitide deserve another chance?

Lancet Oncol. 2014 Dec;15(13):e584-e585. doi: 10.1016/S1470-2045(14)70462-0. Epub 2014 Nov 24.

3

Does cilengitide deserve another chance?-Authors' reply.

Lancet Oncol. 2014 Dec;15(13):e585-e586. doi: 10.1016/S1470-2045(14)71121-0. Epub 2014 Nov 24.

4

End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma.

Neuro Oncol. 2015 May;17(5):634-5. doi: 10.1093/neuonc/nov018. Epub 2015 Feb 13.

5

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Neuro Oncol. 2015 May;17(5):708-17. doi: 10.1093/neuonc/nou356. Epub 2015 Mar 11.

6

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.

7

Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?

Neuro Oncol. 2015 Nov;17(11):1425-7. doi: 10.1093/neuonc/nov198. Epub 2015 Sep 15.

8

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.

J Neurooncol. 2016 May;128(1):163-171. doi: 10.1007/s11060-016-2094-0. Epub 2016 Mar 2.

9

MGMT methylation in glioblastoma: tale of the tail.

Neuro Oncol. 2015 Jan;17(1):167-8. doi: 10.1093/neuonc/nou319. Epub 2014 Nov 13.

10

Neuro-oncology: The many challenges of treating elderly glioblastoma patients.

Nat Rev Neurol. 2015 Jul;11(7):374-5. doi: 10.1038/nrneurol.2015.82. Epub 2015 May 19.

引用本文的文献

1

Glioblastoma Cell Migration, Invasion and Vasculogenic Mimicry Downmodulated by Novel uPAcyclin Derivatives.

Cells. 2025 Feb 12;14(4):259. doi: 10.3390/cells14040259.

2

Real-time morphometric analysis of targeted therapy for neuroblastoma cells in monolayer and 3D hydrogels using digital holographic microscopy.

iScience. 2024 Oct 23;27(11):111231. doi: 10.1016/j.isci.2024.111231. eCollection 2024 Nov 15.

3

Simultaneous inhibition of discoidin domain receptor 1 and integrin αVβ3 radiosensitizes human glioblastoma cells.

Am J Cancer Res. 2023 Oct 15;13(10):4597-4612. eCollection 2023.

4

Synthesis of Novel Carborane-Containing Derivatives of RGD Peptide.

Molecules. 2023 Apr 14;28(8):3467. doi: 10.3390/molecules28083467.

5

Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway.

Cells. 2022 Jun 30;11(13):2078. doi: 10.3390/cells11132078.

6

Inhibition of angiogenesis and tumor progression of MK-0429, an integrin αvβ antagonist, on oral squamous cell carcinoma.

J Cancer Res Clin Oncol. 2022 Dec;148(12):3281-3292. doi: 10.1007/s00432-022-04100-3. Epub 2022 Jun 17.

7

Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?

Pharmaceutics. 2022 May 13;14(5):1053. doi: 10.3390/pharmaceutics14051053.

8

The Effects of αvβ3 Integrin Blockage in Breast Tumor and Endothelial Cells under Hypoxia In Vitro.

Int J Mol Sci. 2022 Feb 3;23(3):1745. doi: 10.3390/ijms23031745.

9

Anti-Cancer Effects of Cyclic Peptide ALOS4 in a Human Melanoma Mouse Model.

Int J Mol Sci. 2021 Sep 3;22(17):9579. doi: 10.3390/ijms22179579.

10

APLN/APLNR Signaling Controls Key Pathological Parameters of Glioblastoma.

Cancers (Basel). 2021 Aug 2;13(15):3899. doi: 10.3390/cancers13153899.